key: cord-1035447-1dqaap1r
authors: Ngami, A; Guelfucci, F; Bianic, F; Net, P
title: POSC198 Impact of COVID-19 on Influenza Vaccine Coverage Rate During the 2020/2021 Season
date: 2022-01-31
journal: Value in Health
DOI: 10.1016/j.jval.2021.11.672
sha: 530d71a6702c467cf61c3cd4e329448882d55a3e
doc_id: 1035447
cord_uid: 1dqaap1r

Objectives: The 2020/21 influenza season was marked by the co-circulation of the Sars-CoV-2 responsible for the COVID-19 pandemic, and strong incentives supporting influenza vaccination were issued by governments to protect their populations. The objective of this study was to assess the evolution of influenza vaccine coverage rate (VCR) under the COVID-19 pandemic. Methods: We conducted secondary desk research to collect annual influenza VCR for the seasons 2010/11 to 2020/21 in France, Italy, Spain, UK, Canada and US. Government and public health agency websites were consulted and VCR were extracted for all populations eligible to influenza vaccination. Stakeholders were contacted by email when information was not available. We used non-parametric Wilcoxon signed-rank tests to investigate significant variations in VCR per eligible group for the 2020/21 season compared to previous seasons. Results: VCRs for the 2020/21 season were not available for Italy and Spain, and VCRs for Canada were only available from the season 2015/16 onwards. Overall VCR in France increased by 15.58% in 2020/21 compared to previous seasons (p=0.001). Significant increases in VCR in both adults aged 65+ years and below 65 years at-risk were observed in France (+15.55% / +11.60%;all p=0.001 ) and the UK (+10.89% / +7.68%;all p=0.001). In the US where influenza immunization is recommended for all individuals aged 6 months and above, significant increases in VCR were noted for the 2020/21 season in the following age groups: 18+ years (+39.69%), 18-49 years (+57.52%), 50-64 years (+36.30%) and 65+ years (+14.86%) (all p=0.001). No significant changes were observed for all eligible groups in Canada. Conclusions: Significant augmentations in influenza VCR were observed during the 2020/21 season, probably in reaction to the COVID-19 pandemic. Analyses for Italy and Spain should be conducted once data is available and surveillance of VCR should be pursued as the pandemic is still ongoing.

Molnar D, 1 Azam AK, 1 Meszaros K, 1 Jamet N, 1 George M, 2 Khanduri P, 3 Roiz J, 3 Casabona G 1 1 GSK, Wavre, Belgium, 2 Hari Thrivikramji, Wavre, Belgium, 3 Evidera, London, UK Objectives: Economic evaluations of varicella vaccination typically consider only outpatient varicella cases. However, varicella complications can occur, requiring additional diagnostic procedures or hospitalizations. Therefore, their inclusion in such models should be considered. This systematic literature review aimed at identifying the prevalence and duration of complications, and case-fatality rates among patients with primary varicella. Methods: Prospective and retrospective observational studies, reported worldwide in English between 1999-2020 were included. The search was performed in Medline and EMBASE. The following complications were assessed: bacterial skin infection, soft tissue infection, pneumonia, encephalitis, cerebellitis/acute cerebellar ataxia, meningitis, febrile seizure, hematological complications, gastroenteritis/diarrhea, dehydration, and systemic varicella complications. Results: A total of 130 eligible studies were identified. Across studies, the proportion of patients who had developed some form of varicella complication ranged from 0.17% to 98.70% across studies. The most frequently reported complications were skin infection (0.17%-93.00%) and cerebellitis/acute cerebellar ataxia (0.01%-64.50%). Among the less common complications, the prevalence of lower respiratory tract infection was 0.02%-56.50%, encephalitis 0.01%-42.00%, systemic varicella complications 0.08%-50.00%, soft tissue infection (0.01%-60.00%),meningitis 0.00%-19.30%, gastroenteritis/diarrhea 1.43%-43.27%, febrile seizures 0.01%-20.00%, hematological complications 0.02%-45.12%, and dehydration 0.11%-32.80%. The symptoms associated with soft tissue infections lasted for up to 21 days whereas for pneumonia, hematological complications, and gastroenteritis, it lasted between up to 2 and 10 days. The fatality rate for the overall complications ranged from 0.16% to 6.0%. Results varied noticeably depending on whether the studied population comprised all varicella patients, or patients hospitalized with varicella complications. Conclusions: Varicella infection is associated with various complications that may be fatal. To capture the comprehensive burden of varicella and value of preventative measures like vaccination in economic evaluations, including the value of these complications is important in terms of cost and quality of life loss implications. Objectives: Immunisation is the best strategy to protect individuals from Invasive Meningococcal Disease (IMD), however the planned discontinuation of Glax-oSmithKline's (GSK) Hib/MenC vaccine will create a gap in the vaccination schedule at 12 months in the UK National Immunisation Programme (NIP). It is critical to maintain direct protection in this high-risk toddler group against the severe and long-lasting effects of IMD. This model evaluates the public health impact of replacing GSK's MenC component with a MenACWY vaccine for toddlers at 12 months of age. Methods: An incidence-based static population model was developed to simulate the impact of vaccination on the epidemiology of IMD in England using a 30-year time horizon. This timeframe corresponds to progressive introduction of the MenACWY vaccine. Compared to the use of MenC/Hib, the impact on public health was examined when a MenACWY vaccine is introduced into the schedule (base-case); and when no vaccination is given at 12 months of age (scenario analysis). Main outcomes include: IMD cases avoided (with or without sequelae) and IMD deaths avoided. Results: The base-case analysis indicated that introducing vaccination with a quadrivalent MenACWY at 12 months was associated with improved health outcomes. Protection against IMD caused by serogroup C would be maintained. Furthermore, an additional 255 cases of IMD could be avoided over 30 years with the introduction of a quadrivalent vaccine due to the additional protection against serogroups W and Y. In contrast, no replacement at 12 months would result in 174 additional serogroup C IMD cases over the 30-year timeframe. Conclusions: A routine immunisation programme with a quadrivalent MenACWY vaccine for toddlers would ensure that this high-risk population has broad, direct protection against IMD caused by multiple serogroups.

Brasseur P Miracor Medical, Geneva, Switzerland Objectives: Aim was to examine the relationship between gender and HF after STEMI in patients with no prior history of HF. Methods: A literature review was performed. Only publications looking at gender difference for HF in STEMI and including at least 500 women were retained. No other restriction was applied. Results: 5 publications were identified. The most recent publication (10'443 patients -3,112 women) concluded that, after covariate adjustment for risk factors, HF at hospital presentation was significantly higher for women (25.1% vs 20.0% ; OR: 1.34; 95% CI : 1.21 -1.48), with a higher 30-day mortality (25.1% vs 20.6% ; OR: 1.29 ; 95% CI: 1.05 -1.58). A study linking administrative databases in Alberta (45'064 patients, 45.1% STEMI , 30.8% women) showed that STEMI women had a higher unadjusted rate of developing in-hospital HF (15.2% vs 9.5%); This difference remained significant after adjustment (aOR : 1.26 ; 95% CI : 1.13-1.4). After 1 year and 5 years, women remained at higher risk of developing HF with adjusted subdistribution hazard ratios of 1.21 (95% CI : 1.12-1.3) and 1.18 (95% CI : 1.11-1.24), respectively. In Poland, for STEMI patients with incomplete reperfusion after pPCI (766 (35%), rehospitalization because of HF was significantly higher in women at 6 months (12.5 % vs 7.5%, p = 0.016), 12 months (13.9% vs 9.4%, p = 0.044) and at 2 years (18.8% vs 11.7%, p= 0.006). In a pooled patient-level data from 10 randomized pPCI trials (2'632 STEMI patients), women (23% of patients) had a higher 1-year rate HF hospitalization (5.6% vs 1.7% ; p , 0.0001). This contrasts with a in Singapore with 7'597 STEMI patients (13.8% women). After adjusting for baseline characteristics and treatment, gender difference in risk of 1-year rehospitalization for HF was almost inexistent (HR : 1.05 ; 95% CI : 0.79 to 1.40). Conclusions: Women appear to be at higher risk of developing de novo HF after STEMI.

Ngami A, Guelfucci F, Bianic F, Net P Syneos Health, Montrouge, France Objectives: The 2020/21 influenza season was marked by the co-circulation of the Sars-CoV-2 responsible for the COVID-19 pandemic, and strong incentives supporting influenza vaccination were issued by governments to protect their populations. The objective of this study was to assess the evolution of influenza vaccine coverage rate (VCR) under the COVID-19 pandemic. Methods: We conducted secondary desk research to collect annual influenza VCR for the seasons 2010/11 to 2020/21 in France, Italy, Spain, UK, Canada and US. Government and public health agency websites were consulted and VCR were extracted for all populations eligible to influenza vaccination. Stakeholders were contacted by email when information was VALUE IN HEALTH -JANUARY 2022 not available. We used non-parametric Wilcoxon signed-rank tests to investigate significant variations in VCR per eligible group for the 2020/21 season compared to previous seasons. Results: VCRs for the 2020/21 season were not available for Italy and Spain, and VCRs for Canada were only available from the season 2015/16 onwards. Overall VCR in France increased by 15.58% in 2020/21 compared to previous seasons (p=0.001). Significant increases in VCR in both adults aged 65+ years and below 65 years at-risk were observed in France (+15.55% / +11.60% ; all p=0.001 ) and the UK (+10.89% / +7.68% ; all p=0.001). In the US where influenza immunization is recommended for all individuals aged 6 months and above, significant increases in VCR were noted for the 2020/21 season in the following age groups: 18+ years (+39.69%), 18-49 years (+57.52%), 50-64 years (+36.30%) and 65+ years (+14.86%) (all p=0.001). No significant changes were observed for all eligible groups in Canada. Conclusions: Significant augmentations in influenza VCR were observed during the 2020/21 season, probably in reaction to the COVID-19 pandemic. Analyses for Italy and Spain should be conducted once data is available and surveillance of VCR should be pursued as the pandemic is still ongoing. Objectives: The purpose of this study was to use real-world, longitudinal data to evaluate clinical characteristics, treatment patterns, and healthcare resource use (HCRU) for Japanese non-dialysis-dependent (NDD) chronic kidney disease (CKD) patients with anaemia. Methods: This retrospective cohort study used annual health checkup and claims data from the Japan Medical Data Center. Adults ($18 years) in Japan with $1 year of look-back data from initial NDD-CKD anaemia diagnosis, defined by established age-sex hemoglobin cut-off levels or any anemia treatment, and estimated glomerular filtration rate (eGFR) ,60 mL/min/1.73m 2 were included. HCRU-associated costs resulting from hospital, outpatient, and emergency care; procedures; and medications were evaluated from April 2016 to March 2018. Clinical characteristics, treatment patterns, and HCRU-associated costs were summarised descriptively. Results: Among 5,908 included NDD-CKD patients with anaemia, mean age was 51.7 years, 4084 (69.1%) were male, mean (standard deviation, SD) baseline hemoglobin was 12.0 (1.35) g/dL, and mean (SD) eGFR was 51.2 (11.90) mL/ min/1.73m 2 (Stage 3a 81.0%). 552 (9.3%) received erythropoiesis-stimulating agent (ESA) monotherapy or concomitant treatment, usually oral/intravenous iron (39.9%). In ESA-treated patients, mean (SD) baseline haemoglobin was 11.2 (1.29) g/dL. ESAtreated patients were more frequently in Stage 4-5 CKD (74.5%) than those receiving iron treatment (15.3%) or no treatment (3.4%). Proportions of no treatment for anaemia decreased (Stage 3a: 79.7%, 3b: 73.1%, 4: 31.7%, 5: 13.9%) while ESA treatment increased as CKD worsened (Stage 3a: 1.4%, 3b: 14.3%, 4: 60.5%, 5: 82.4%). Monthly HCRU-associated costs in ESA-treated patients (median 75,435 JPY/month, interquartile range [IQR] 42, 780) were numerically greater compared to all NDD-CKD anaemia patients (9,579 JPY/month, 3,054-24,533), iron-treated patients (12, 011 JPY/month, 4, 718) , and no treatment patients (8, 128 JPY/ month, 2, 406) . Conclusions: As CKD severity increased, anaemia nontreatment decreased and ESA use increased. ESA-treated patients incurred greater HCRU-associated costs relative to other Japanese NDD-CKD patients with anaemia.

Harris L, 1 L'Italien G, 1 Croop R, 1 Coric V, 1 Robbins J, 1 Woolley J, 2 OConnell T 2 1 Biohaven Pharmaceuticals, New Haven, CT, USA, 2 Medicus Economics, Boston, MA, USA Objectives: In England, NICE clinical guidelines on acute management of migraine recommend first-line use of an oral triptan, followed by a non-oral triptan if first-line treatment is ineffective or not tolerated.

[1] NHS formularies further suggest trial of tablet formulations before orodispersible tablets and oral lyophilisates.[2-3] New acute therapies with novel mechanisms of action may offer relief for patients who progress beyond first-line triptan tablets. [4] This study aimed to assess the size of this patient population, using recent triptan prescription data for England. Methods: Annual prescription totals in England, by triptan formulation, were identified using NHS England's Prescription Cost Analysis (PCA) 2020.

[5] PCA data were restricted to prescriptions containing "triptan" in the "BNF Chemical Substance Name" field (excluding oxitriptan, which is not used for migraine [6] ) then further classified into tablet and non-tablet formulations. Route of administration was determined based on review of the "BNF Presentation Name" and "Unit of Measure" fields. Prescription shares were calculated as the sum of the "Total Quantity" field for relevant formulations, divided by the sum of the field for all triptan formulations. Results: In England in 2020, 16.8% of triptan prescriptions were for non-tablet formulations (4,661,566 of 27,688,318) . These included orodispersible tablets (rizatriptan and zolmitriptan) (7.3%), oral lyophilisates (rizatriptan) (4.0%), nasal sprays (sumatriptan and zomitriptan) (3.8%), and solution for subcutaneous injection (sumatriptan) (1.7%). The non-tablet share of triptan prescriptions in 2020 remained consistent with prior years (e.g., 17.5% in 2017 [7]). Conclusions: Prescription data for England suggest that 15%-20% of migraine patients progress beyond tablet triptan formulations recommended for first-line acute management, which may inform estimates of the patient population eligible for new acute therapies.

Headaches in over 12s: diagnosis and management

Jo Y, 1 Kim S, 2 Yu YM 3 1 Yonsei University, Incheon, 41, South Korea, 2 Seoul National University, Seoul, Korea, Republic of (South), 3 Yonsei University, Incheon, Korea, Republic of (South) Objectives: The renin-angiotensin system (RAS) may play an important role in neurodegenerative diseases. Several studies have found that RAS inhibitors have preventive effects against Parkinson's disease (PD). However, these effects have not been demonstrated conclusively. This study aimed to investigate the association between the use of RAS inhibitors and PD occurrence. Methods: We conducted a nationwide population-based cohort study. Older individuals (age $ 60 years) who had been diagnosed with angina between January 1, 2009 and June 31, 2009 were recruited and followed up until December 31, 2019 using the Korean Health Insurance Review and Assessment database. The association between PD incidence and RAS inhibitor use was evaluated through Cox proportional hazard regression analyses. The data were adjusted for age, sex, comorbid disease, and concomitant medications. A 1-year lag time was applied to minimize reverse causality of PD. Results: Of the 117,093 subjects, 32,583 were new users of RAS inhibitors, while 84,510 did not use RAS inhibitors. 1,934 PD cases with an overall incidence rate of 1.94 PD cases per 1,000 person-years were recorded during 10 years of follow-up. The results showed that the use of RAS inhibitors was associated with a reduced risk of PD incidence compared with their non-use (adjusted hazard ratio [aHR] 0.76; 95% confidence interval [Cl]: 0.68-0.84). Specifically, the use of angiotensin-II receptor blockers (ARBs) exhibited a reduced risk of PD incidence (aHR 0.77; 95% CI: 0.68-0.87). However, a statistically significant association was not observed in the case of angiotensin-converting enzyme inhibitors (ACEIs) (aHR 0.85; 95% CI: 0.72-1.00). Conclusions: Our study suggests that using RAS inhibitors may be associated with a reduced risk of PD. However, a statistically significant risk reduction in PD incidence was observed in the case of ARB use, but not in the case of ACEI use.